课题基金 / 基金详情

Development of the new retroviral vector system for stem cell gene therapy.

Development of the new retroviral vector system for stem cell gene therapy.
开发用于干细胞基因治疗的新型逆转录病毒载体系统。
批准号:
18591180
负责人:
ONODERA Masafumi
金额:
$2.04万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

ONODERA Masafumi的其他基金

相似基金

相关文献

中文摘要
翻译
我们已经做了下面的实验来开发用于干细胞基因治疗临床试验的新的逆转录病毒转导系统。1)细胞色素b558重链(CYBB)基因的克隆:目标疾病是x连锁慢性肉芽肿病(CGD), CYBB基因突变,其编码蛋白gp9l^<phox>无功能,导致以肉芽肿形成为特征的严重细菌和真菌感染。利用健康对照多核细胞mRNA反转录cDNA, PCR扩增该基因的开放阅读框(ORF)。ORF序列(1603bp)得到了验证。2)基因沉默耐药逆转录病毒载体GCDNsap的构建:通过在临床逆转录病毒载体Gcsap中插入不与YY1、Trim28等负转录因子结合的突变,构建GCDNsap。该载体允许在未成熟细胞(如造血干细胞或胚胎干细胞)中稳定表达转导基因。3)逆转录病毒产生克隆的建立:在四环素(tet off系统)控制下,将CYBB cDNA克隆的载体转导到表达水疱性口炎病毒衍生G蛋白(VSV-G)的293gpg细胞中,转化为相应的逆转录病毒。病毒滴度约为2.0x10^5 ml/I。在Jurkat细胞上进行分析。4) gp91^<phox>在转导细胞中的表达:通过流式细胞仪检测该基因在转导细胞表面或细胞质上的表达。人类CD34^+细胞的转导实验正在进行中
英文摘要
We have done experiments below to develop the new retroviral transduction system used in stem cell gene therapy clinical trials.1) Cloning of the cytochrome b558 heavy chain (CYBB) gene: The target disease is X-linked chronic granulomatous disease (CGD) in which the CYBB gene is mutated and its coding protein gp9l^<phox> is non-functional, resulting in severe bacterial and fungal infections characterized by formation of granulomas. The open reading frame (ORF) of the gene was amplified by the PCR technique using cDNA reverse-transcribed from mRNA isolated from polynuclear cells of healthy control. The sequence of the ORF (1603bp) was certified.2) Construction of the gene silencing resistant retroviral vector GCDNsap: GCDNsap was constructed by inserting mutations into the clinical retroviral vector Gcsap not to bind to the negative transcription factors such as YY1 and Trim28. The vector allows stable expression of the transduced genes in immature cells such as hematopoietic stem cells or embryonic stem cells.3) Establishment of retroviral producer clones: The vector cloned with the CYBB cDNA was converted to the corresponding retrovirus by transduction into the 293gpg cell that expressed vesicular stomatitis virus derived G protein (VSV-G) under the control of tetracycline (tet off system). The virus titer was approximately 2.0x10^5 ml/I. U. assayed on Jurkat cell.4) Expression of gp91^<phox> in transduced cells: Expression of the gene on the surface or cytoplasm of transduced cells was determined by FACS. Transduction experiments into human CD34^+ cells are under way
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1253/circj.71.138
发表时间: 2007-01-01
期刊: CIRCULATION JOURNAL
影响因子: 3.3
作者: [Maruyama, Hidekazu, Watanabe, Shigeyuki, Yamaguchi, Iwao]
通讯作者: Yamaguchi, Iwao
FEASIBLITY OF VACCINE THERAPY WITH DENDRITIC CELLS GENETIC ALLY MODIFIED TO EXPRESS THE TUMOR-ASSOCIATED ANTIGEN HER2
通过基因修饰表达肿瘤相关抗原 HER2 的树突细胞进行疫苗治疗的可行性
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Tsukasa Nabekura, Toshiro Nagasawa, Hiromitsu Nakauchi, and Masafumi Onodera]
通讯作者: and Masafumi Onodera
An immunotherapy approach with dendritic cells gentically modified to express the tumor-associated antigen,HER2
一种免疫治疗方法,使用经过基因修饰的树突状细胞来表达肿瘤相关抗原 HER2
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Tsukasa Nabekura, Toshiro Nagasawa, Hiromitsu Nakauchi, and Masafumi Onodera]
通讯作者: and Masafumi Onodera
蛍光蛋白質を発現とるトランスジェニック非ヒト動物
表达荧光蛋白的转基因非人类动物
DOI: --
发表时间: 2006
期刊:
影响因子: --
作者: []
通讯作者:
共 26 条
    Analysis of mechanisms of chronic GVHD post allo-SCT by marking with multicolor florescent proteins
    国内基金
    海外基金
    基于CRISPR/Cas9文库筛选蜱传病毒Tamdy virus感染相关宿主因子及其作用机制的研究
    • 批准号:
      --
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2022
    • 负责人:
      周宏
    • 依托单位:
    DNA糖苷酶OGG1调节PARP1介导的EB病毒潜伏蛋白表达的机制研究
    基于寨卡病毒NS1和NS5的海洋微生物中抗病毒化合物的发现
    • 批准号:
      81973204
    • 项目类别:
      面上项目
    • 资助金额:
      56.0万元
    • 批准年份:
      2019
    • 负责人:
      宋福行
    • 依托单位:
    苹果茎沟病毒(Apple stem grooving virus, ASGV)CP基因介导的RNAi 转基因对ASGV侵染和脱毒的影响研究
    • 批准号:
      31801709
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      21.0万元
    • 批准年份:
      2018
    • 负责人:
      冯超红
    • 依托单位: